Duopharma to proceed with niche products


Some Duopharma products

KUALA LUMPUR: Duopharma Biotech Bhd, which recorded stronger earnings in the third quarter ended Sept 30, will push ahead with its foray into specialty products as one of its strategies to create a pool of niche products.

The company in a statement yesterday said that it had recently obtained registration approval and launched Erysaa, an Erythropoeitin (EPO) product. EPO is the protein present in the human body that adjusts the red blood cell generation in accordance with the oxygen requirement of the human body.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Duopharma , niche , products , EPO , profit ,

Next In Business News

ACE Market-bound GHS posts 1Q net profit of RM1.5mil
AAX redesignates Benyamin Ismail as GM, appoints Bo Lingam as group CEO
Favelle Favco secures RM76.3mil crane orders
IJM confirms MACC, IRB presence at office
CAB Cakaran buys industrial building in Pahang for RM2.8mil
Ringgit firms against greenback on economic resilience
PJBumi forms JV with Chinese firm for oilfield equipment production
Malaysia-born billionaire investor Cheah Cheng Hye puts quarter of wealth in gold
Rianlon’s RM1.27bil project boosts Johor’s high-value manufacturing push
Opensys wins RM22mil cash recycling machines supply contract

Others Also Read